Inotrem lands $25M to fund sepsis R&D, focuses on the TREM-1 path
By Nuala Moran
Monday, March 17, 2014
A new company has been founded with €18million (US$25 million) in series A funding to have another go at scaling the sheer cliffs of sepsis. Inotrem SA will focus on the TREM-1 (triggering receptor expressed on myeloid cells) pathway, which functions as an amplifier of the immune response and is markedly up-regulated in patients suffering from sepsis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.